Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients with Myocardial Infarction and No-reflow

Prospective RandomizEd Study Comparing Glycoprotein IIb/IIIa Inhibitors VERsus Standard Therapy in PatientS with Myocardial Infarction and Angiographic Evidence of No-reFLOW

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02739711

Acronym

REVERSE-FLOW

Enrollment

120

Registered

2016-04-15

Start date

2016-07-31

Completion date

2025-12-31

Last updated

2025-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Brief summary

Aim of the study is to examine the effects of glycoprotein IIb/IIIa inhibitors on reperfusion success assessed by cardiac magnetic resonance imaging in patients with myocardial infarction and angiographic evidence of no-reflow.

Interventions

DRUGGlycoprotein IIb/IIIa inhibitors

Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ST-elevation myocardial infarction and non-ST-elevation myocardial infarction \<48 h after symptom onset * Angiographic evidence of no-reflow (Thrombolysis in Myocardial Infarction-flow grade ≤2) after primary percutaneous coronary intervention * Age ≥18 years * Informed consent

Exclusion criteria

* ST-elevation myocardial infarction and non-ST-elevation myocardial infarction patients with Thrombolysis in Myocardial Infarction-flow 3 after primary percutaneous coronary intervention * Age ≤18 years * Known pregnancy, breast-feeding or intend to become pregnant during the study period * Contraindication for treatment with platelet inhibitors * Known allergy to glycoprotein IIb/IIIa inhibitors, aspirin, or heparin * Active peptic gastric or duodenal ulcer * History of major surgery (including intracranial or intraspinal) \<4 weeks * Active bleeding or bleeding diathesis * Stroke \<2 years (ischemic and hemorrhagic) * Known coagulation defect or relevant thrombocytopenia * Arteriovenous malformations or aneurysm * Severe liver insufficiency * Renal insufficiency requiring dialysis * Uncontrolled hypertension * Hypertensive retinopathy * Vasculitis * Fibrinolysis \<12 hours * Contraindication for cardiac magnetic resonance imaging at study entry * Patients without informed consent * Participation in another trial

Design outcomes

Primary

Measure	Time frame
Infarct size assessed by cardiac magnetic resonance imaging	Day 1-10 after myocardial infarction

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026